Molecular Neurobiology

, Volume 36, Issue 1, pp 102–112

The Cannabinoid CB1 Receptor Antagonist, Rimonabant, as a Promising Pharmacotherapy for Alcohol Dependence: Preclinical Evidence


    • C.N.R. Institute of Neuroscience
  • Alessandro Orrù
    • Department of NeuroscienceUniversity of Cagliari
  • Paola Lai
    • C.N.R. Institute of Neuroscience
  • Claudia Cabras
    • Department of NeuroscienceUniversity of Cagliari
  • Paola Maccioni
    • C.N.R. Institute of Neuroscience
  • Marina Rubio
    • Department of Biochemistry and Molecular BiologyComplutense University
  • Gian Luigi Gessa
    • C.N.R. Institute of Neuroscience
  • Mauro A. M. Carai
    • C.N.R. Institute of Neuroscience

DOI: 10.1007/s12035-007-0017-y

Cite this article as:
Colombo, G., Orrù, A., Lai, P. et al. Mol Neurobiol (2007) 36: 102. doi:10.1007/s12035-007-0017-y


Several lines of preclinical evidence indicate the ability of the prototypic cannabinoid CB1 receptor antagonist, rimonabant, to suppress various alcohol-related behaviors, including alcohol drinking and seeking behavior and alcohol self-administration in rats and mice. Together, these data—synthetically reviewed in the present paper—suggest (a) the involvement of the cannabinoid CB1 receptor in the neural substrate controlling alcohol intake, alcohol reinforcement, and the motivational properties of alcohol and (b) that rimonabant may constitute a new and potentially effective medication for the treatment of alcohol dependence.


Cannabinoid CB1 receptor antagonist, rimonabantAlcoholAlcohol dependence (alcoholism)Alcohol drinking and seeking behaviorAnimal models of alcoholism

Copyright information

© Humana Press Inc. 2007